Workflow
SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

Core Insights - SeaStar Medical Holding Corporation has published a health economic analysis indicating that the QUELIMMUNE therapy can save approximately $69,146 per hospitalization for pediatric patients with Acute Kidney Injury (AKI) in the ICU compared to standard continuous renal replacement therapy (CRRT) [1][4] - The QUELIMMUNE therapy has shown a 77% survival rate in treated patients, representing a potential ~50% reduction in loss of life compared to historical data [3][8] - The therapy is currently being adopted by leading children's medical centers, which may enhance its broader acceptance in the healthcare market [2] Economic Impact - The analysis estimates that the QUELIMMUNE therapy could offset its own costs, potentially leading to no out-of-pocket expenses for institutions for a median treatment duration of 6 days [1][4] - Modeled hospitalization costs for pediatric patients treated with QUELIMMUNE are estimated at $320,304, significantly lower than $457,092 and $389,451 for patients in the KID and ppCRRT cohorts respectively [4] Clinical Efficacy - QUELIMMUNE therapy has received FDA approval under a Humanitarian Device Exemption for pediatric patients with AKI due to sepsis, showing no dialysis required for survivors at Day 60 post-treatment [3][7] - A pivotal trial, NEUTRALIZE-AKI, is underway to evaluate the safety and efficacy of the SCD therapy in adults with AKI, which has received FDA Breakthrough Device Designation [4][10] Technology Overview - The QUELIMMUNE therapy utilizes patented Selective Cytopheretic Device (SCD) technology aimed at modulating the immune response to prevent destructive hyperinflammation in critically ill patients [11][14] - This therapy is the only FDA-approved option for treating life-threatening AKI due to sepsis in critically ill pediatric patients, addressing a significant unmet medical need [14]